New product intros [brolucizumab, elexacaftor/tezacaftor/ivacaftor (new combination), fedratinib hydrochloride, glucagon (new formulation), pretomanid, rifamycin (new indication/new formulation), ropeginterferon alfa-2b, roxadustat (first-in-class), STR-01, treosulfan (new indication)]
Keyword(s):
Keyword(s):
Keyword(s):